J Bubenik
Overview
Explore the profile of J Bubenik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
204
Citations
571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stepanek I, Indrova M, Bieblova J, Fucikova J, Spisek R, Bubenik J, et al.
J Biol Regul Homeost Agents
. 2012 Jan;
25(4):517-29.
PMID: 22217985
Maturation of dendritic cells (DC) towards functional antigen-presenting cells is a complex process, the regulation of which may also involve epigenetic mechanisms. Thus, it is of interest to investigate how...
2.
Simova J, Pollakova V, Indrova M, Mikyskova R, Bieblova J, Stepanek I, et al.
Br J Cancer
. 2011 Oct;
105(10):1533-41.
PMID: 22015556
Background: Epigenetic mechanisms have important roles in the tumour escape from immune responses, such as in MHC class I downregulation or altered expression of other components involved in antigen presentation....
3.
Simova J, Bubenik J, Rossner P, Bubenikova D, Jandlova T
Oncol Rep
. 2011 May;
4(6):1161-3.
PMID: 21590213
The experiments were designed to examine whether direct in vivo transfer of plasmid DNA not carrying any 'therapeutic' genes ('empty' plasmid DNA) can influence tumour growth. Murine MC-induced sarcoma Mc12...
4.
Bubenik J
Int J Oncol
. 2011 May;
2(6):1049-52.
PMID: 21573669
The toxicity of high IL-2 doses required for therapy of generalized neoplasms limits at present the large-scale application of IL-2 treatment to the management of cancer. In 1988, it was...
5.
Bubenik J, Zeuthen J, Indrova M, Bubenikova D, Simova J
Int J Oncol
. 2011 May;
4(1):13-6.
PMID: 21566882
The present study was designed to examine the kinetics and function of peritoneal exudate cells (PEC) during local interleukin 2 (IL-2) gene therapy of the X63-Ag8.653 plasmacytoma growing in the...
6.
Bubenik J
Int J Oncol
. 2011 May;
6(1):45-9.
PMID: 21556499
Cytokine gene therapy has recently become a new prospective modality in the treatment of cancer. Active immunization with gene-modified tumour cells in experimental systems employs either live Vaccines at subthreshold,...
7.
Indrova M, Bubenik J, Jakoubkova J, Sobota V, Helmichova E, Simova J
Int J Oncol
. 2011 May;
7(3):523-6.
PMID: 21552869
The present prospective study was designed to assess whether the renal cell carcinoma (RCC) patients treated with recombinant interferon alpha (IFN alpha), whose tumours respond (responders) and do not respond...
8.
Bubenik J, Simova J, Vondrys P, Vonka R, Kitasato H, Bostik P, et al.
Int J Oncol
. 2011 May;
8(3):477-81.
PMID: 21544385
Experiments were designed to investigate the effects of murine recombinant IL-2 used as adjuvant for tumour vaccines in two model systems. The first system employed the Syrian hamster K3/II cell...
9.
Rossner P, Bubenik J, Indrova M, Sobota V, Vondrys P, Zeuthen J, et al.
Int J Oncol
. 2011 May;
10(1):77-82.
PMID: 21533347
Two genes, the gene coding for IL-2 and the gene encoding the CD80 molecule, were inserted into murine sarcoma MC12 cells. Tumorigenicity of a variety of cell clones with different...
10.
Bubenik J, Rossner P, Bubenikova D, Simova J, Indrova M, Sloncova E
Int J Oncol
. 2011 Apr;
11(6):1213-9.
PMID: 21528325
Experiments were designed to investigate immunogenicity and therapeutic efficacy of tumour vaccines constructed by transfection of poorly immunogenic murine sarcoma Mc12 with synergistic CD80 and IL-2 genes. Immunization/challenge experiments demonstrated...